A new drug from Biogen called BIIB080 has shown promising early results in reducing levels of tau protein, a toxic protein linked to Alzheimer's disease. A Phase Ib trial found that the drug reduced tau levels in the brains of people with early-stage Alzheimer's by 60%. BIIB080 is an antisense oligonucleotide (ASO) drug that works by targeting messenger RNA associated with tau, halting the production of the protein. The drug was licensed from Ionis and differs from other tau-targeting antibody therapies that have had limited success.
Reducing tau levels is important because it is more closely related to clinical and cognitive symptoms of Alzheimer's compared to amyloid beta, which is the start of the disease process. Only when toxic tau proteins start to accumulate do the first symptoms of the disease occur. The study involved 46 patients, with the primary endpoint being safety and tolerability, and biomarker data as an exploratory endpoint. The results showed that the drug reduced soluble tau protein in cerebrospinal fluid in a dose-dependent manner, with doses ranging across 10mg, 30mg, 60mg, and 115mg. The drug also reduced aggregated tau pathology, as measured by positron emission tomography in all brain composites assessed.
While the results are still early, the drug's potential breakthrough in reversing tau protein accumulation is significant. Most researchers have presumed that combining drugs with different modes of action will be necessary to generate significant progress against Alzheimer's, but BIIB080 could go on to show a clear clinical benefit as a monotherapy. Biogen is not making any claims about how this will translate into clinical benefits, but expectations will be raised for its ongoing Phase II CELIA study, where the company aims to enroll around 735 patients.
BIIB080 is administered through intrathecal injection. This route of administration involves injecting the drug directly into the cerebrospinal fluid in the spinal canal. While this method allows for targeted delivery of the drug to the central nervous system, it may also limit the widespread use of the drug, particularly in early-onset patients.
An intrathecal injection is an invasive procedure that requires specialized equipment and trained medical personnel. It is typically reserved for patients with severe or life-threatening conditions, such as cancer-related pain or spinal cord injuries. The need for repeated injections may also pose a challenge for patients and caregivers.
Additionally, the use of intrathecal injection may limit the patient population that can benefit from the drug. Patients with early-onset disease may not be good candidates for this route of administration, as it can be difficult to administer in younger patients, and the risks may outweigh the potential benefits.
Despite these limitations, intrathecal injection remains a promising method for delivering therapeutic agents to the central nervous system. It allows for targeted delivery of the drug, which can reduce the risk of side effects and improve treatment outcomes. As research into BIIB080 continues, it will be important to assess the feasibility of intrathecal injection as a route of administration and to determine which patient populations can benefit most from this approach.
Resources
Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?